Age-related growth hormone-releasing activity of growth hormone secretagogues in humans.

Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Abstract Text:

Growth hormone-releasing peptides (GHRPs) are synthetic molecules with strong, dose-related and reproducible growth hormone (GH)-releasing activity in humans. GHRPs act at both the pituitary and the hypothalamic level, where specific receptors have been located. In adults, GHRPs release more GH than does GH-releasing hormone (GHRP), whilst their co-administration has a synergistic effect, indicating that they have, at least partially, different mechanisms of action. However, normal activity of GHRH-secreting neurones is needed to achieve the full GH-releasing effect of GHRPs. In contrast to GHRH, the GH-releasing activity of GHRPs is not further increased by substances acting via inhibition of hypothalamic somatostatin, and is only blunted by substances that stimulate hypothalamic somatostatin release. Even free fatty acids and exogenous somatostatin, which act directly on somatotrophs, do no more than blunt the effect of GHRPs. Thus, the GH-releasing activity of GHRPs is partially refractory to inhibitory influences, GHRPs act, at least in part, by antagonism of somatostatin activity, both at the pituitary and the hypothalamic level. The GH-releasing effect of GHRPs is not dependent on gender, but undergoes age-related variations. Gonadal steroids seem to influence the activity of GHRPs only in childhood. The reduced GH response to GHRPs in the elderly is probably due mainly to concomitant GHRH hypoactivity and somatostatinergic hyperactivity. A preserved GH-releasing effect of GHRPs has been reported in acromegaly, anorexia nervosa, hyperthyroidism and in critically ill patients. GHRPs have also been found to increase GH release in children with idiopathic short stature, in GH deficiency and in obese patients, in whom there is a well-known reduction of somatotroph function. The GH response to GHRPs is markedly reduced in hypothyroidism and Cushing's syndrome.

Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Publishing Authors By Initials

For similar endocrine system: endocrine glands: pituitary gland research abstracts see: endocrine system: endocrine glands: pituitary gland research

PUBMED ID PMID:

MEDLINE DATE:

Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Journal Published:

PUBLICATION TYPE: Review

Journal: Acta paediatrica (Oslo, Norway : 1992). Supplement

VOLUME: 423

Page Numbers: 92-6

Journal Abbreviation: Acta Paediatr Suppl

ISSN: 0803-5326

DAY: 12

MONTH: Nov

YEAR: 1997

Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Information

Number of References: 66

LANGUAGE: eng

NlmUniqueID: 9315043

Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Keywords Mesh Terms:

KEYWORDS: Pituitary Gland

MESH TERMS: drug effects

Chemical & Substance for Abstract: Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Information

Substance Name: Growth Hormone-Releasing Hormone

Registry Number: 9034-39-3

Grant and Affiliation Information for Age-related growth hormone-releasing activity of growth hormone secretagogues in humans.

AFFILIATION: Department of Internal Medicine, University of Turin, Italy.

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Paediatr Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Age-related growth hormone-releasing activity of growth hormone secretagogues in humans Related Publications

• Acylated ghrelin inhibits spontaneous luteinizing hormone pulsatility and responsiveness to naloxone but not that to gonadotropin-releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis.
• Age-related growth hormone-releasing activity of growth hormone secretagogues in humans.
• Changes in awakening cortisol response and midnight salivary cortisol are sensitive markers of strenuous training-induced fatigue.
• Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific.
• Diagnosis of adult GH deficiency.
• Endocrine actions of cortistatin: In vivo studies.
• Escherichia coli biofilms.
• GHRH and GH secretagogues: clinical perspectives and safety.
• Ghrelin: endocrine, metabolic and cardiovascular actions.
• Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors.
• Obestatin Promotes Survival of Pancreatic {beta}-Cells and Human Islets and Induces Expression of Genes Involved in the Regulation of {beta}-Cell Mass and Function.
• Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.
• Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy.
• The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress.
• The amino acid valine is secreted in continuous-flow bacterial biofilms.
• The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend?